A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes
The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2 diabetes). This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792).
Participation in the study will last about 18 months.
Inclusion Criteria:
Have body mass index (BMI) ≥30 kilograms per square meter (kg/m2) or BMI ≥25.0 kg/m2 and at least 1 of the following weight-related comorbidities at screening:
Have a history of at least one unsuccessful dietary effort to lose body weight
Exclusion Criteria:
Sun City West, Arizona 85375, United States
CABA, 1204, Argentina
Luoyang Shi, 471003, China
Shinjuku-ku, 160-0008, Japan
Suita-shi, 565-0853, Japan
Yamato-shi, 242-0004, Japan